A Phase 2, Prospective, Interventional, Open-Label, Multi-Site, Extension Study to Assess the Long-Term Safety and Tolerability of TAK-935 (OV935) as Adjunctive Therapy in Patients With Rare Epilepsy
Phase of Trial: Phase II
Latest Information Update: 18 Feb 2019
At a glance
- Drugs TAK 935 (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENDYMION
- Sponsors Takeda
- 25 Sep 2018 Planned End Date changed from 19 Dec 2020 to 21 Mar 2023.
- 25 Sep 2018 Planned primary completion date changed from 18 Jul 2020 to 21 Mar 2023.
- 15 Aug 2018 Status changed from planning to recruiting.